New monthly shot could simplify mental health treatment
NCT ID NCT07185815
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a long-acting injection of cariprazine given once a month, instead of daily pills, for people with schizophrenia, bipolar I disorder, or major depression. The trial involves 24 clinically stable adults and will check safety, side effects, and how well the drug works. It is still in early stages, so results are not yet known.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cariprazine (long-acting injection)
What this could lead to
If successful, this could offer a convenient once-monthly injection for people with schizophrenia, bipolar disorder, or depression, potentially improving treatment adherence.
What could go wrong
This is an early-phase trial with only 24 participants, so safety and effectiveness are not yet proven. The injection may cause side effects or not work as well as daily pills.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER (MDD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mapi Pharma Investigational Site IL-001
RECRUITINGTel Aviv, 6423906, Israel
Contact
-
Mapi Pharma Investigational Site IL-003
RECRUITINGNess Ziona, 741000, Israel
Contact
-
Mapi Pharma Investigational Site IL-004
RECRUITINGBeersheba, 8461144, Israel
Contact
-
Mapi Pharma Investigational Site IL-005
RECRUITINGRamat Gan, 56621, Israel
Contact
-
Mapi Pharma Investigational Site IN-101
RECRUITINGAhmedabad, 380008, India
Contact
-
Mapi Pharma Investigational Site IN-102
RECRUITINGAhmedabad, 380016, India
Contact